Long-term efficacy of infliximab in hidradenitis suppurativa

Journal of Dermatological Treatment

Volumn 23, Issue 4, 2012, Pages 278-283

  Paradela, Sabela ^a   Rodríguez Lojo, Romina ^a   Fernández Torres, Rosa ^a   Arévalo, Pilar ^a   Fonseca, Eduardo ^a  

^a Oral and Maxillofacial Surgery Service University Hospital of La Coruña   (Spain)

Author keywords

Hidradenitis; Infliximab; Tumor necrosis factor alpha

Indexed keywords

INFLIXIMAB;

ABSCESS; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE ACTIVITY; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG TOLERANCE; DRUG WITHDRAWAL; FEMALE; FOLLICULITIS; HUMAN; MALE; ONSET AGE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELAPSE; SUPPURATIVE HIDRADENITIS; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; ANTIBODIES, MONOCLONAL; DERMATOLOGIC AGENTS; FEMALE; HIDRADENITIS SUPPURATIVA; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84863923875     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.3109/09546634.2012.683767     Document Type: Article

References (46)

1. Consensus definition adopted by the second international HS Symposium by the Hidradenitis Suppurativa Foundation, San Francisco 2009. Available from http://www.hs-foundation.org/abouths/what. htm.Accessed August 2011.
2. Revuz J. Hidradenitis suppurativa. JEADV. 2009;23:985-998.
3. Wolkenstein P, Loundou A, Barrau K, Auquier P, Revuz J; Quality of Life Group of the French Society of Dermatology. Quality of life impairment in hidradenitis suppurativa: A study of 61 cases. J Am Acad Dermatol. 2007;56:621-623.
4. Pedraz J, Daudén E. Practical management of hidradenitis suppurativa. Actas Dermosifiliogr. 2008;99:101-110.
5. Grant A, Gonzalez T, Montgomery MO, Cardenas V, Kerdel FA. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: A randomized, double-blind, placebocontrolled crossover trial. J Am Acad Dermatol. 2010;62:205-217.
6. Adams DR, Yankura JA, Fogelberg AC, Anderson BE. Treatment of hidradenitis suppurativa with etanercept injection. Arch Dermatol. 2010;146:501-504.
7. Miller I, Lynggaard CD, Lophaven S, Zachariae C, Dufour DN, Jemec GB. A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa. Br J Dermatol. 2011;165:391-398.
8. Remicade, INN-Infliximab-EMA. Available from http://www.ema. europa.eu/docs/en-GB/document-library/EPAR-Product-Informa tion/human/000240/ WC500050888.pdf.Accessed August 2011.
9. Hurley HJ. Axillary hiperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa, and familial benign pemphigus: SURGICAL approach. In Roenigk RK, Roenigk HHJ, editors. Dermatologic surgery, principles and practice. New York, NY: MARCEL Dekker, 1989. p. 729-739.
10. Sartorius K, Lapins J, Emtestam L, Jemec GB. Suggestions for uniform outcome variables when reporting treatment effects in hidradenitis suppurativa. Br J Dermatol. 2003;149:211-213.
11. Lebwohl B, Sapadin AN. Infliximab for the treatment of hidradenitis suppurativa. J Am Acad Dermatol. 2003;49(5 Suppl):S275-S276.
12. Sullivan TP, Welsh E, Kerdel FA, Burdick AE, Kirsner RS. Infliximab for hidradenitis suppurativa. Br J Dermatol. 2003;149:1046-1049.
13. Adams DR, Gordon KB, Devenyi AG, Ioffreda MD. Severe hidradenitis suppurativa treated with infliximab infusion. Arch Dermatol. 2003;139: 1540-1542.
14. Thielen AM, Barde C, Saurat JH. Long-term infliximab for severe hidradenitis suppurativa. Br J Dermatol. 2006;155:1105-1107.
15. Usmani N, Clayton TH, Everett S, Goodfield MD. Variable response of hidradenitis suppurativa to infliximab in four patients. Clin Exp Dermatol. 2007;32:204-205.
16. Pedraz J, Daudén E, Pérez-Gala S, Goiriz-Valdés R, Fernández-Peas P, Garcia-Diez A. Hidradenitis suppurativa. Response to treatment with infliximab. Actas Dermosifiliogr. 2007;98:325-331.
17. Mekkes JR, Bos JD. Long-term efficacy of a single course of infliximab in hidradenitis suppurativa. Br J Dermatol. 2008;158:370-374.
18. Goertz RS, Konturek PC, Naegel A, Janka R, Amann K, Maennlein G, et al. Experiences with a long-term treatment of massive gluteal acne inversa with infliximab in Crohn's disease. Med Sci Monit. 2009;15:CS14-CS18.
19. Torres T, Selores M. Treatment of hidradenitis suppurativa with infliximab. An Bras Dermatol. 2010;85:576.
20. Lasocki A, Sinclair R, Foley P, Saunders H. Hidradenitis suppurativa responding to treatment with infliximab. Australas J Dermatol. 2010; 51:186-190.
21. Deschamps ME, Payet S, Tournadre A, Soubrier M, Souteyrand P, D'Incan M. Efficacy of infliximab in the treatment of follicular occlusion triad. Ann Dermatol Venereol. 2010;137:546-550.
22. Alecsandru D, Padilla B, Izquierdo JA, Fernández-Cruz E, Sánchez- Ram'n S. Severe refractory hidradenitis suppurativa in an HIVpositive patient successfully treated with infliximab. Arch Dermatol. 2010;146:1343-1345.
23. Roussomoustakaki M, Dimoulios P, Chatzicostas C, Kritikos HD, Romanos J, Panayiotides JG, et al. Hidradenitis suppurativa associated with Crohn's disease and spondyloarthropathy: Response to anti-TNF therapy. J Gastroenterol. 2003;38:1000-1004.
24. Fardet L, Dupuy A, Kerob D, Levy A, Allez M, Begon E, et al. Infliximab for severe hidradenitis suppurativa: Transient clinical efficacy in 7 consecutive patients. J Am Acad Dermatol. 2007;56:624-628.
25. Fernández-Vozmediano JM, Armario-Hita JC. Infliximab for the treatment of hidradenitis suppurativa. Dermatology. 2007;215:41-44.
26. Moschella SL. Is there a role for infliximab in the current therapy of hidradenitis suppurativa? A report of three treated cases. Int J Dermatol. 2007;46:1287-1291.
27. Brunasso AM, Delfino C, Massone C. Hidradenitis suppurativa: Are tumour necrosis factor-alpha blockers the ultimate alternative? Br J Dermatol. 2008;159:761-763.
28. Haslund P, Lee RA, Jemec GB. Treatment of hidradenitis suppurativa with tumour necrosis factor-alpha inhibitors. Acta Derm Venereol. 2009;89:595-600.
29. Brunasso AM, Massone C. Treatment of hidradenitis suppurativa with tumour necrosis factor-alpha inhibitors: An update on infliximab. Acta Derm Venereol. 2011;91:70-71.
30. Clemmensen OJ. Topical treatment of hidradenitis suppurativa with clindamycin. Int J Dermatol. 1983;22:325-328.
31. Jemec GB, Wendelboe P. Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa. J Am Acad Dermatol. 1998;39:971-974.
32. Mortimer PS, Dawber RP, Gales MA, Moore RA. A double-blind controlled cross-over trial of cyproterone acetate in females with hidradenitis suppurativa. Br J Dermatol. 1986;115:263-268.
33. Paradela S, Fonseca E. Treatment of hidradenitis suppurativa. Treat Strateg Dermatol. 2011;1:92-95.
34. Kraft JN, Searles GE. Hidradenitis suppurativa in 64 female patients: Retrospective study comparing oral antibiotics and antiandrogen therapy. J Cutan Med Surg. 2007;11:125-131.
35. Boer J, van Gemert MJ. Long-term results of isotretinoin in the treatment of 68 patients with hidradenitis suppurativa. J Am Acad Dermatol. 1999;40:73-76.
36. Kaur MR, Lewis HM. Hidradenitis suppurativa treated with dapsone: A case series of five patients. J Dermatolog Treat. 2006;17:211-213.
37. Ritz JP, Runkel N, Haier J, Buhr HJ. Extent of surgery and recurrence rate of hidradenitis suppurativa. Int J Colorectal Dis. 1998;13:164-168.
38. Watson JD. Hidradenitis suppurativa - a clinical review. Br J Plast Surg. 1985;38:567-569.
39. Harrison BJ, Mudge M, Hughes LE. Recurrence after surgical treatment of hidradenitis suppurativa. Br Med J (Clin Res Ed). 1987;294: 487-489.
40. Mandal A, Watson J. Experience with different treatment modules in hidradenitis suppurativa: A study of 106 cases. Surgeon. 2005;3: 23-26.
41. van der Zee HH, de Ruiter L, van den Broecke DG, Dik WA, Laman JD, Prens EP. Elevated levels of tumour necrosis factor (TNF)-a, interleukin (IL)-1b and IL-10 in hidradenitis suppurativa skin: A rationale for targeting TNF-a and IL-1b. Br J Dermatol. 2011; 164:1292-1298.
42. Matusiak L, Bieniek A, Szepietowski JC. Increased serum tumour necrosis factor-alpha in hidradenitis suppurativa patients: Is there a basis for treatment with anti-tumour necrosis factor-alpha agents? Acta Derm Venereol. 2009;89:601-603.
43. Fimmel S, Zouboulis CC. Comorbidities of hidradenitis suppurativa (acne inversa). Dermatoendocrinol. 2010;2:9-16.
44. Vander Cruyssen B, Durez P, Westhovens R, De Keyser F. Seven-year follow-up of infliximab therapy in rheumatoid arthritis patients with severe long-standing refractory disease: Attrition rate and evolution of disease activity. Arthritis Res Ther. 2010;12:R77.
45. Brunasso AM, Massone C. Rotational therapy with TNF-alpha blockers for recalcitrant hidradenitis suppurativa. Eur J Dermatol. 2010;20: 644-646.
46. van Rappard DC, Mekkes JR. Treatment of severe hidradenitis suppurativa with infliximab in combination with surgical interventions. Br J Dermatol. In press.